Telix Pharmaceuticals is trading 4.89% down at $9.10; no clear company-specific catalyst has been identified for the October 30 decline. - The company announced a December 1 shareholder meeting concerning its previously announced ITM acquisition, but available information does not establish that announcement as the reason for the drop. - Healthcare was sharply higher, supported by strong Merck and Eli Lilly results, so the sector move does not explain Telix Pharmaceuticals’ decline.